A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: Treatment rationale and protocol dynamics

Clinical Lung Cancer

Volumn 14, Issue 4, 2013, Pages 461-465

  Georgoulias, Vassilis ^a   Douillard, Jean Yves ^b   Khayat, David ^c   Manegold, Christian ^d   Rosell, Rafael ^e,f   Rossi, Antonio ^g   Menez Jamet, Jeanne ^h   Iché, Marina ^h   Kosmatopoulos, Kostas ^h   Gridelli, Cesare ^g  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f INSTITUT UNIVERSITARI DEXEUS   (Spain)

^g S G MOSCATI HOSPITAL   (Italy)

^h Vaxon Biotech   (France)

Author keywords

Clinical trial; First line; Metastatic recurrent non small cell lung cancer (NSCLC); Telomerase reverse transcriptase (TERT); Vaccination

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MONTANIDE ISA 51; PEPTIDE; PLACEBO; TUMOR MARKER; TYROSYLLEUCYLPHENYLALANYLPHENYLALANYLTYROSYLARGINYLLYSYLSERYLVALINE; UNCLASSIFIED DRUG; VX 001;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; INFORMED CONSENT; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR IMMUNITY;

ADOLESCENT; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; TELOMERASE;

EID: 84878813349     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.02.001     Document Type: Article

References (22)

1. GLOBOCAN Cancer fact sheets: lung cancer 2008 http://globocan.iarc.fr/ factsheets/cancers/lung.asp Accessed: October 7, 2012
2. M.A. Socinski, R. Crowell, T.E. Hensing Treatment of non-small cell lung cancer, stage IV. ACCP evidence-based clinical practice guidelines. (2nd edition) Chest 132 3 suppl 2007 277S 289S
3. S. Peters, A.A. Adjei, C. Gridelli Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 7 suppl 2012 vii56 vii64
4. A. Sandler, R. Gray, M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
5. M. Reck, J. von Pawel, P. Zatloukal Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol 21 2010 1804 1809
6. F. Cappuzzo, T. Ciuleanu, L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
7. L. Paz-Ares, F. Marinis, M. Dediu et al. PARAMOUNT: final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) J Clin Oncol 30 suppl 2012 abstract LBA7507 http://www.asco.org Accessed: April 15, 2013
8. A. Rossi, R. Pasquale, C. Esposito Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat Rev 39 2013 489 497
9. A. Rossi, P. Maione, C. Schettino Non-small-cell lung carcinoma vaccines in clinical trials Expert Rev Vaccines 10 2011 887 897
10. A. Hoos, G. Parmianni, K. Hege A clinical development paradigm for cancer vaccines and related biologics J Immunother 30 2007 1 15
11. N.W. Kim, M.A. Piatyszek, K.R. Prowse Specific association of human telomerase activity with immortal cells and cancer Science 266 1994 2011 2015
12. R.H. Vonderheide, W.C. Hahn, J.L. Schultze The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes Immunity 10 1999 673 679
13. Y. Fujita, T. Fujikane, S. Fujiuchi The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma Cancer 98 2003 1008 1013
14. S. Tourdot, A. Scardino, E. Saloustrou A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes Eur J Immunol 30 2000 3411 3421
15. A. Scardino, D.A. Gross, P. Alves HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy J Immunol 168 2002 5900 5906
16. D.A. Gross, S. Graff-Dubois, P. Opolon High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy J Clin Invest 113 2004 425 433
17. E.K. Vetsika, E. Papadimitraki, D. Aggouraki Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients J Immunother 34 2011 641 650
18. D. Mavroudis, I. Bolonakis, S. Cornet A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies Oncology 70 2006 306 314
19. A. Kotsakis, E.K. Vetsika, S. Christou Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study Ann Oncol 23 2012 442 449
20. I. Bolonaki, A. Kotsakis, E. Papadimitraki Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide J Clin Oncol 25 2007 2727 2734
21. E.K. Vetsika, G. Konsolakis, D. Aggouraki Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001 Cancer Immunol Immunother 61 2012 157 168
22. P. Goldstraw, J. Crowley, K. Chansky The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2 2007 706 714